Pune, Feb. 26, 2025 (GLOBE NEWSWIRE) — Tumor Profiling Market Size & Growth Analysis:<\/b><\/p>\n
\u201cAccording to SNS Insider, The Tumor Profiling Market<\/a> <\/b>size was valued at USD 10.5 billion in 2023 and is projected to reach USD 24.8 billion by 2032, expanding at a CAGR of 10.04% from 2024 to 2032.\u201d<\/i><\/p>\n Tumor Profiling Market Poised for Exponential Growth fueled by the increasing prevalence of cancer, advancements in genomic technologies, and the growing adoption of personalized cancer treatments.<\/p>\n Get a Sample Report of Tumor Profiling Market@\u00a0https:\/\/www.snsinsider.com\/sample-request\/5694<\/a><\/b><\/p>\n Tumour profiling market\u2002is primarily driven by increase in cases of cancer across the globe. Cancer has become the second leading cause of death globally, as\u2002per the World Health Organization (WHO), with nearly 10 million deaths in 2023. Tumor profiling is an essential aspect of understanding the genetic profile of tumors, allowing healthcare providers to personalize the treatment plans according to the individual profiles of\u2002the patient. It is this method that has led to a\u2002much more successful treatment outcome and decreased adverse effects which has fuelled the trend of tumor profiling technologies. Technological advancements in genomics and sequencing and bioinformatics\u2002have catalyzed the growth of the market. The advent of next-generation sequencing (NGS) and polymerase chain reaction\u2002(PCR) technologies have transformed tumor profiling by enabling high-throughput, precise and economical analysis of the tumor genome. Moreover, artificial intelligence (AI) and machine learning (ML) technologies have transformed data analysis in tumor\u2002profiling, allowing for the discovery of new biomarkers and therapeutic targets. <\/p>\n Government initiatives and funding for cancer research have also contributed to market expansion. For instance, the U.S. National Cancer Institute (NCI) allocated USD 6.9 billion in 2023 for cancer research, including tumor profiling studies. Similarly, the European Union’s Horizon Europe program has invested heavily in precision medicine projects, further boosting the market.<\/p>\n Major Players Analysis Listed in this Report are:<\/b><\/p>\n Tumor Profiling Market Report Scope<\/b><\/p>\n Segmentation Analysis<\/b><\/p>\n By Technique<\/b><\/p>\n The genomics segment held the largest share of 37% of the total revenue in the tumor profiling market in 2023. Genomics refers to the study of the full DNA sequence of an individual in\u2002order to screen for mutations, genes expression levels, and other genetic changes that can cause cancer. This\u2002approach is often used in clinical practice to direct treatment decisions, predict patient outcomes, and highlight novel therapeutic pathways. The growth of this segment\u2002has been pushed by the increasing use of genomic testing in oncology in addition to the decreasing costs of sequencing. Other technologies like proteomics, metabolomics, and epigenetics are also gaining popularity and providing complementary\u2002information about tumor biology.<\/p>\n By Technology<\/b><\/p>\n In 2023, the Sequencing\u2002technology dominated the tumor profiling market with a revenue share of 30%. Next-generation sequencing (NGS) has been the most commonly used sequencing technology to date for accurately and\u2002rapidly analyzing multiple genes at once. NGS has\u2002become a cornerstone of precision oncology, allowing the missing of rare mutations and complex genomic alterations. Wide use of qPCR, immunohistochemistry (IHC), and additionally in situ hybridization (ISH) are also widely used for tumor profiling, particularly in resource-limited settings. Continuous innovation\u2002in sequencing platforms as well as the development of portable sequencing devices is likely to further propel the growth of the market.<\/p>\n By Application<\/b><\/p>\n In 2023, personalized cancer medicine was the dominant application segment, with 41% share\u2002of the total market. Tumor profiling plays a crucial role\u2002in personalized medicine, as it allows for the identification of genetic changes that can be targeted with specific therapies. Such data-driven strategy revolutionizes cancer therapy, bringing better treatment outcomes with less risk for side\u2002effects. Other applications of tumor profiling include Oncological Diagnostics, and Research. The growing emphasis on precision medicine and the increasing availability of targeted therapies are expected to drive the demand for tumor profiling in personalized cancer medicine.<\/p>\n For A Detailed Briefing Session with Our Team of Analysts, Connect with Us Now@ https:\/\/www.snsinsider.com\/request-analyst\/5694<\/a><\/b><\/p>\n Tumor Profiling Market Segmentation<\/b><\/p>\n By Technique<\/b><\/p>\n By Technology<\/b><\/p>\n By Application<\/b><\/p>\n Regional Insights<\/b><\/p>\n North America dominated the tumor profiling market in 2023, accounting for approximately 45% of the global market share. The advanced healthcare infrastructure, greater adoption of precision medicines, and large investments in cancer research contribute\u2002to regional leadership. Driven by the presence of leading pharmaceutical and biotechnology companies, including Illumina,\u2002Thermo Fisher Scientific, and Foundation Medicine, the U.S. makes the most significant contribution to the North American market. Market growth has also been further expedited by government initiatives like the Cancer Moonshot program to stimulate innovation and collaboration across the\u2002cancer research spectrum.<\/p>\n The\u2002tumor profiling market in Asia-Pacific is projected to record the highest growth during the forecast period. Asia-Pacific is projected to witness\u2002significant growth owing to rapid advancements in healthcare infrastructure, high patient awareness levels regarding precision medicine, and rising healthcare spending. With government backing and collaborations with global\u2002pharmaceutical firms, countries including China, India, and Japan are pouring money into cancer research and genomics. For instance, China’s National Health Commission has launched several programs to improve cancer diagnosis and treatment, including the adoption of tumor profiling technologies.<\/p>\n Recent Developments<\/b><\/p>\n![](\"https:\/\/ml.globenewswire.com\/Resource\/Download\/866d8f76-5c48-41ff-a1f9-21efb7cb40d6\/tumor-profiling-market.jpg\" "\\"Tumor-Profiling-Market.jpg\\"")
<\/b><\/p>\n\n
\n
\n Report Attributes<\/strong><\/td>\n Details<\/strong><\/td>\n<\/tr>\n \n Market Size in 2023<\/td>\n US$ 10.5 Billion<\/td>\n<\/tr>\n \n Market Size by 2032<\/td>\n US$ 24.8 Billion<\/td>\n<\/tr>\n \n CAGR<\/td>\n CAGR of 10.04% From 2024 to 2032<\/td>\n<\/tr>\n \n Base Year<\/td>\n 2023<\/td>\n<\/tr>\n \n Forecast Period<\/td>\n 2024-2032<\/td>\n<\/tr>\n \n Historical Data<\/td>\n 2020-2022<\/td>\n<\/tr>\n \n Key Regional Coverage<\/td>\n North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East]), Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia Rest of Latin America)<\/td>\n<\/tr>\n<\/table>\n \n
\n
\n
\n
\n
\n
![\"\"](\"https:\/\/ml.globenewswire.com\/media\/YzVkZmJlYjYtYmZmNi00ZDgwLTkwMTctZDRlNTQ5NjUxYjdlLTEyNjg4MTk=\/tiny\/SNS-Insider-pvt-ltd.png\")
\n <\/div>\n","protected":false},"excerpt":{"rendered":"